BrainsWay
Manufacturing · Israel · 51-200 Employees
View Company Info for Free
Overview
Headquarters
16 Hartum St, Jerusalem, Jerusalem, 9777...Phone Number
+97225824030Website
www.brainsway.comRevenue
$49.1 MillionStock Symbol
BWAYIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About BrainsWay
BrainsWay is a global medical technology company specializing in advanced noninvasive neurostimulation solutions for treating mental health and neurological disorders. The company develops and commercializes its proprietary Deep Transcranial Magnetic Stimulation platform, providing innovative treatment technologies for conditions including depression, obsessive-compulsive disorder, smoking addiction, and other psychiatric and neurological disorders. BrainsWay serves healthcare providers, hospitals, and medical centers worldwide, advancing brain health through clinically supported medical device innovation.Explore more
BrainsWay Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BrainsWay your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once BrainsWay has new funding data
Check if BrainsWay has recently received funding, and reach out quickly before it becomes old news!
BrainsWay, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when BrainsWay launches new products
Click to see if BrainsWay had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on BrainsWay recently announced quarterly report
Website visits: Recent activity has been detected on your website
Check out if BrainsWay is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at BrainsWay
Recommended Actions
Reach out to Masked Content who joined BrainsWay as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
BrainsWay is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
BrainsWay is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about BrainsWay.
BrainsWay financials insights
Gather financial insights about BrainsWay, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Stock/Share Issuance
$20M
BrainsWay Tech Stack
A closer look at the technologies used by BrainsWay
Most Recent Scoops
Earnings
BrainsWay has reported remaining performance obligations of $80.4 million as of June 30, 2026, a 30% increase compared with the same period last year, reflecting strong market demand for Deep TMS and the success of its leasing strategy focused on enterprise customers.
Earnings, Finance
Earnings
BrainsWay has reported cash flow from operations of $6.3 million in Q2 2026, compared with $1.2 million in Q1 2026, with the company maintaining a debt-free capital structure as of the end of the quarter.
Earnings, Business Finance, Finance, Financial Operations
Earnings
BrainsWay has reported adjusted EBITDA of $3.5 million for Q2 2026, a 141% increase compared with $1.5 million in the same period last year, with adjusted EBITDA margin expanding to 20% from 11%.
Earnings, Finance
Earnings
BrainsWay has reported sales and marketing expenses of $4.9 million for Q2 2026, steady with Q2 2025, reflecting continued operating leverage and improved efficiency across its sales organization.
Earnings, Sales, Finance, Marketing Operations
Earnings
Spending/Investment, Research & Development
BrainsWay News & Media
BrainsWay Deep TMS™ Study Shows 70% Reduction in Patients Experiencing Suicidal Ideation
Peer-reviewed secondary analysis adds to growing body of clinical evidence supporting the potential role of Deep TMS in addressing suicidal ideation among patients with major depressive disorder Peer-reviewed secondary analysis adds to growing body of clinical evidence supporting the potential role of Deep TMS in addressing suicidal ideation among patients with major depressive disorderBrainsWay (BWAY) Q2 2026 Earnings Call Transcript
Revenue jumped 35% to $17.1 million as system shipments surged 42%.Brainsway Q2 Earnings Call Highlights
Brainsway (NASDAQ:BWAY) reported second-quarter revenue growth of 35% and raised its full-year 2026 revenue outlook, citing continued demand for its Deep TMS systems, expanding reimbursement for its accelerated SWIFT treatment protocol and growth in its installed base. Revenue for the three monthsBrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights
Record second quarter 2026 revenue increased 35% to $17.1 million, compared with Q2 2025
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding BrainsWay
Sign Up For FreeTo access detailed company insights
BrainsWay is a global medical technology company specializing in advanced noninvasive neurostimulation solutions for treating mental health and neurological disorders. The company develops and commercializes its proprietary Deep Transcranial Magnetic Stimulation platform, providing innovative treatment technologies for conditions including depressi... Read More
